Instalab
logoInstalab

Acetylcholine Receptor Blocking Antibody

Blood Test
Help investigate drooping eyelids, double vision, and muscle weakness that worsens with use.
4.9 (4,257 reviews)
Tested by Quest Diagnostics
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home or at 2,000+ patient service centers
Get results
Explained with clear next steps, no medical jargon

Should you take a Acetylcholine Receptor Blocking Antibody test?

This test is most useful if any of these apply to you.

Noticing Drooping Eyelids or Double Vision
This can support a myasthenia evaluation when your symptoms and examination fit, usually alongside binding antibodies.
Being Evaluated for Myasthenia
Blocking activity adds information about your antibody pattern, though binding testing usually contributes more to diagnosis.
Living With Eye-Only Myasthenia
This describes one part of your antibody pattern; its ability to predict spread beyond the eyes remains unproven.
Reviewing an Unexpected Positive Result
Reviewing symptoms, treatment history, and other antibody tests can help determine whether an unexpected result is meaningful.

About Acetylcholine Receptor Blocking Antibody

Maybe your eyelids droop or your vision doubles by evening and then recovers after rest. These symptoms can occur when your immune system interferes with the signals that tell your muscles to move. The acetylcholine receptor blocking antibody test checks for one kind of antibody activity involved in myasthenia gravis.

Myasthenia gravis causes muscle weakness that often worsens with repeated use. Blocking antibody testing is an established laboratory test used as an adjunct in its diagnosis, usually alongside the more sensitive binding antibody test. Its proposed uses for predicting disease severity, spread beyond the eyes, or treatment response remain exploratory.

How the Blocking Test Works

Acetylcholine is the chemical a nerve releases to make a muscle contract. It attaches to receptors on the muscle's surface where nerve meets muscle. In AChR-antibody-positive myasthenia gravis, antibodies interfere with these receptors and weaken signal transmission.

The antibodies can cause damage in several ways. Some activate complement. This group of immune proteins can damage the surface of the muscle at the nerve-muscle junction. Others cause receptors to be pulled into the muscle cell and broken down, or interfere with acetylcholine attaching to them. These activities overlap, so binding, blocking, and modulating antibodies aren't three completely separate populations.

This test uses serum separated from a blood sample. The lab mixes muscle receptors with your serum and a radioactively tagged snake toxin called alpha-bungarotoxin. A competitive radioimmunoassay measures how much the serum prevents that tracer from attaching to the receptors.

The result is reported as percent inhibition. A higher percentage means greater interference with tracer binding under the assay's conditions. It doesn't represent the percentage of receptors blocked in your body, your percentage loss of muscle strength, or your chance of having myasthenia.

The three AChR antibody tests measure different properties. In one laboratory series, 4,740 serum samples were positive on at least one of them:

TestWhat it detectsPositive among these antibody-positive samples
BindingAntibodies that attach to the receptorAbout 88%
ModulatingAntibody activity that promotes removal of receptors from the cell surfaceAbout 70%
BlockingAntibody activity that inhibits the laboratory tracer's attachmentAbout 65%

Binding and blocking testing together detected about 97% of the antibody-positive samples in that series. Clinical diagnoses weren't available, so these figures describe detection among positive specimens, not how often the tests diagnose myasthenia in everyone who has it.

In an older study of 349 people with myasthenia, blocking antibodies were found in about half. Blocking was never the only positive result, partly because the modulating assay used in that study also detected blocking activity. A negative blocking result alongside a positive binding result is therefore quite possible.

Myasthenia Gravis Diagnosis

A positive result can support myasthenia gravis when your symptoms and examination fit. An isolated antibody result needs more careful interpretation when the symptoms suggest another cause.

Most published diagnostic performance estimates concern AChR binding antibodies. Conventional binding testing detects antibodies in roughly 85 to 90% of people with generalized myasthenia and 50 to 70% of those with weakness limited to the eyes. Those figures don't describe the sensitivity of this blocking assay. Myasthenia can occur even when all routine AChR antibody tests are negative.

Myasthenia can also occur with a thymoma. This is a tumor of the thymus gland in the chest. A blocking result doesn't establish whether a thymoma is present.

Eye-Only Weakness That Spreads

Some people with ocular myasthenia later develop weakness in the throat, limbs, neck, or breathing muscles. Researchers have studied whether blocking antibodies help identify who will develop this more widespread form.

A Greek study followed 47 people who already had detectable AChR binding antibodies for an average of 2.8 years. Thirteen had begun with eye-only symptoms. All eight whose weakness later became generalized had blocking antibodies, while none of the five who remained ocular did.

That is a striking finding in a very small, selected group. It hasn't established a reliable way to calculate your personal risk from a blocking result. A negative result also can't guarantee that weakness will remain limited to your eyes.

Related evidence comes from a study of 223 people with ocular myasthenia. Those who later developed generalized weakness had average starting antibody levels about three times higher. That study measured serum binding antibodies, which are a different measurement from blocking activity.

Severity and Myasthenic Crisis

A Chinese study of 148 people found blocking antibodies in about 43% of the group and 58% of those with generalized disease. Higher inhibition was associated with greater weakness and with myasthenic crisis. A crisis involves severe breathing-muscle weakness that requires ventilatory support. An association with crisis doesn't establish that a blocking result can predict when one will happen.

The findings haven't been consistent. In an Argentinian study of 75 people with AChR-antibody-positive myasthenia, higher blocking activity was associated with milder disease and findings suggesting less complement activation. This doesn't prove that blocking antibodies protect against severe disease.

Differences between the people studied and the assays used may contribute to these conflicting results, but they haven't been resolved. There is no validated blocking percentage that forecasts how weak you will become or whether you will have a crisis.

Newborns of Mothers With Myasthenia

Maternal AChR antibodies can cross the placenta and cause temporary weakness in some newborns. An older study linked more severe neonatal disease to blocking activity measured using decamethonium. That research assay differed from the alpha-bungarotoxin assay used for this test.

Those findings don't establish routine blocking testing as a reliable predictor of your baby's condition. Planning observation after birth depends on your myasthenia history and the maternity and newborn teams' assessment.

When Results Can Be Misleading

  • A positive result that doesn't fit your symptoms: false-positive or clinically unexplained results can occur. In a 20-year study at one center, about 14% of people with positive AChR binding results were judged not to have myasthenia. Those were binding measurements and don't provide a false-positive rate for this blocking test.
  • Recent anesthesia with muscle relaxants: older research documented false-positive blocking and modulating results after general anesthesia involving these drugs. This finding shouldn't be generalized to every anesthetic or to every AChR assay.
  • Recent IVIG: a conference case report described temporary binding-antibody positivity after an infusion of pooled donor antibodies and proposed passive antibody transfer as the explanation. This is limited evidence involving the binding assay; it doesn't establish a predictable effect on blocking results.
  • Differences between assays: receptor preparations, laboratory procedures, and interpretation criteria can differ. A percentage from one assay shouldn't be treated as interchangeable with a percentage from another, including a research assay using live cells.
  • Radioactive tracers and sample quality: recently administered nuclear medicine tracers can interfere with this radioactive laboratory method. A sample with substantial red-cell damage, fat, or bilirubin may also be unsuitable for analysis.

What Serial Results Can Show

Some studies of serum binding antibodies have found that falling levels accompany clinical improvement, including an observational study of 90 people. These findings concern a related antibody measurement and don't establish routine blocking measurements as a treatment-monitoring tool.

The Greek blocking study found an association between blocking activity and severity across repeated observations. Its authors explicitly cautioned that their analyses didn't establish that changes within an individual reliably followed changes in that person's symptoms.

Current guidance bases disease monitoring on weakness, examination findings, and measures of daily function. Routine antibody measurements haven't been shown to improve treatment decisions. A changing percentage can be additional information, but it shouldn't determine treatment on its own.

What Moves This Biomarker

Evidence-backed interventions that affect your Acetylcholine Receptor Blocking Antibody level

↓ Decrease
Efgartigimod treatment
Efgartigimod speeds the removal of circulating antibodies and can improve symptoms in AChR-antibody-positive generalized myasthenia. Blocking activity decreased in a trial substudy that used a functional assay with live cells. This supports an effect on blocking antibodies, but it doesn't establish the size of the change on this test's radioimmunoassay percentage.
MedicationModerate Evidence
↓ Decrease
Immunosuppressive treatment
These medicines treat the autoimmune process in myasthenia. Corticosteroids and medicines such as azathioprine are established options. Older observational research found lower serum AChR binding-antibody levels during immunosuppressive treatment. This is related evidence; a predictable decrease in this blocking percentage hasn't been established.
MedicationModerate Evidence
↓ Decrease
Surgical removal of the thymus gland
Thymectomy can improve disease control in selected people with AChR-antibody-positive myasthenia. Older observational research found lower serum binding-antibody levels after surgery. These measurements support an effect on the autoimmune response, but don't establish a consistent decrease in blocking activity.
ProcedureModerate Evidence
↓ Decrease
Plasma exchange combined with immunosuppressive treatment
Plasma exchange removes antibodies from the blood. In a small study combined with immunosuppressive treatment, serum AChR binding-antibody levels stabilized below their pretreatment levels while symptoms improved. The study measured binding antibodies, so it doesn't quantify the effect on this blocking result.
ProcedureModerate Evidence

Frequently Asked Questions

References

22 studies
  1. Thomas R. Haven, Mark E. Astill, Brian M. Pasi, James B. Carper, Lily L. Wu, Anne E. Tebo, Harry R. HillClinical Chemistry2010
  2. Frank M. Howard, Vanda a. Lennon, Jon Finley, Joseph Y. Matsumoto, Lila R. ElvebackAnnals of the New York Academy of Sciences1987
  3. Katie Tharshana Yoganathan, Alexander Stevenson, Awais Tahir, Ross Sadler, Aleksandar Radunović, Naveed MalekJournal of Neurology2022
  4. Konstantinos Lazaridis, Socrates J. TzartosFrontiers in Immunology2020

Acetylcholine Receptor Blocking Antibody Test

$255
FSA/HSA eligible
No Rx needed
HIPAA compliant